Casgevy Expands to Children Age Two

Company Vertex Pharmaceuticals / CRISPR Therapeutics Event Type Regulatory Label Expansion (FDA Supplemental Approval) Modality Ex Vivo CRISPR/Cas9-Edited Autologous Cell Therapy Asset Casgevy (exagamglogene autotemcel) Target BCL11A Erythroid-Specific Enhancer Disease Area Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia (Pediatric) Summary FDA expanded Casgevy to patients…